MedPath

Neurogenic Inflammation in Peri-implant and Periodontal Diseases

Completed
Conditions
Gingival Crevicular Fluid
Periimplant Sulcular Fluid
Neurogenic Inflammation
Periodontal Diseases
Periimplant Diseases
Registration Number
NCT03663140
Lead Sponsor
Ondokuz Mayıs University
Brief Summary

Regulatory effects of some neuropeptides substance-P (SP), neurokinin-A (NKA), calcitonin gene-linked peptide (CGRP) and neuropeptide-Y (NPY) )on inflammatory responses in periodontal disease has been described; however, the impact of neuropeptide levels are not clearly defined in healthy and diseased peri-implant tissues.ın order to evaluate the situation, thirty-nine implants that have been loaded over the past 12 months and their symmetrically matching teeth were evaluated using a split-mouth study design. Clinical periodontal examinations included the Silness-Löe plaque index, Löe-Silness gingival index, bleeding on probing, probing pocket depth and clinical attachment level parameters were determined. Gingival crevicular fluid (GCF)/Periimplant sulcular fluid (PISF) samples were collected, and the levels of the neuropeptides were determined by enzyme-linked immunosorbent assay. Correlations between GCF/PISF neuropeptide levels and the clinical examination parameters were evaluated in the peri-implant/periodontal soft tissues.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
39
Inclusion Criteria

The main inclusion criteria for patient selection were as follows:

  • Compliance with systematic maintenance care;
  • Adult, non-smoker, systemically healthy
  • Not using any medicament for the last 6 months ;
  • Partially dentated patient treated with implant-supported metal ceramic full crowns and/or fixed partial dentures
  • As the study was split-mouth designed, in each individual at least one implant and one matching tooth in the same mouth symmetrically representing the same tooth group (premolars/molars);
  • A single type of metal ceramic implant restoration that is functional for at least 1 year; and a matching tooth with no dental or endodontic restorations.
Exclusion Criteria
  • Medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease and any other systemic disease affecting lipid metabolism (i.e. impaired glucose tolerance, metabolic syndrome);
  • Compromised immune system;
  • Pregnancy, menopause, or lactation;
  • Ongoing drug therapy that might affect the clinical characteristics of periodontitis and lipid metabolism;
  • Dental treatment during the 6 months prior to data collection.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Gingival crevicular fluid/peri-implant sulcular fluid Level of Substance-P8-10 am on the day following periodontal status assessment.

Substance-P (SP) is a neuropeptide of the tachykinin family and marker of neurogenic inflammation.

Gingival crevicular fluid/peri-implant sulcular fluid Level of Calcitonin gene-related peptide8-10 am on the day following periodontal status assessment.

Calcitonin gene-related peptide (CGRP), another neuropeptide derived from peptidergic nerves and a marker of neurogenic inflammation.

Gingival crevicular fluid/peri-implant sulcular fluid Level of neurokinin-A8-10 am on the day following periodontal status assessment.

Neurokinin-A is a neuropeptide of the tachykinin family and marker of neurogenic inflammation.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath